Navigation Links
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Date:11/19/2009

VIENNA, Austria, November 19 /PRNewswire/ -- AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point. Furthermore, based on this analysis, the AD02 patients from the completed Phase I study will now be offered an AD02 booster vaccination.

AFFiRiS AG announced today, that Alzheimer's vaccine candidate AFFITOPE AD02 will undergo immediate tests for potential efficacy in a Phase II trial. This means that the company can focus its diversified development program for Alzheimer's vaccines earlier than initially planned. The reason for the decision is based on the interim analysis of the preceding Phase I testing.

Dr. Walter Schmidt, CEO and co-founder of the company, explains the company's surprisingly rapid decision: "Both vaccines AD01 and AD02 met the primary phase I endpoints demonstrating safety and tolerability and therefore both qualified for phase II testing. However, as a small biotech with a strong focus on optimized resourcing, we are always keen to prioritize. Based on the first interim analysis of secondary endpoints, which is confidential at this stage, we decided to focus in the first instance on AD02. The Phase II trial will start as early as possible, hopefully early next year."

Dr. Frank Mattner, CSO and co-founder, adds: "It is part of our strategy in the early phase of vaccine development to focus on more than one candidate, if possible. In this way, we diversify our risk. Based on this, we can then back in the first instance the potentially most promising candidate and put the others on hold. This is exactly what we did with our Alzheimer's vaccination program and the outcome in the Phase I trials at this stage enabled us to make this decision earlier than we expected and to offer a booster vaccination to the AD02-treated patients. Finally, we can also redirect our resources which will now be available for our other vaccination programs." AFFiRiS AG can also invest all of the EUR 10 million, paid by licensing partner GSK Biologicals as a milestone payment for the positive completion of the Phase I studies, in the other R&D programs.

The vaccine development program of AFFiRiS is based on the company's AFFITOME(R) technology, which also delivered the vaccines tested so far. Also based on this technology are six other vaccination programs being developed by AFFiRiS AG, which target, among other indications, Parkinson's disease and atherosclerosis.

About AFFiRiS AG (status November 2009):

Based on proprietary patent positions, AFFiRiS has developed tailored peptide vaccines against Alzheimer's Disease, Parkinson's and four other diseases characterized by urgent medical requirement and attractive market volumes. Alzheimer's is the current lead indication and clinical Phase I trials have just been completed on two product candidates. AFFiRiS succeeded in attracting GlaxoSmithKline Biologicals as its licensing partner in October 2008. The contract contains provisions for (milestone-dependent) payments of up to EUR 430 million. Based on the successful completion of two clinical Phase I trials, a payment of EUR 10 million was made in October. AFFiRiS currently employs 60 highly-qualified staff at its premises on the St. Marx Campus in Vienna, Austria (http://www.affiris.com).


    Contact AFFiRiS AG:
    Mag. Agnes Meyer
    Karl-Farkas-Gasse 22
    T +43-1-798-15-75-3
    mailto:agnes.meyer@affiris.com
    http://www.affiris.com

    Copy Editing & Distribution:
    PR&D - Public Relations fur
    Forschung & Bildung
    Campus Vienna Biocenter 2
    1030 Vienna
    T +43-1-505-70-44
    mailto:contact@prd.at
    http://www.prd.at

SOURCE AFFiRiS AG


'/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
2. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
5. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
6. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
8. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
9. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
10. Bavarian Nordic A/S - Half Year Interim Report 2009
11. Arpida Reports Interim Results For Six Months to 30 June 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Composite ended the trading session at 5,817.69, down 0.07%; ... finish at 20,656.58; and the S&P 500 closed at ... session as 4 sectors closed in green, 4 sectors ... the day. This Friday, Stock-Callers.com has initiated reports coverage ...
(Date:3/23/2017)... ... 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event ... companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in ... popularity is due to its new team building format, a way for teams to not ...
(Date:3/23/2017)... LOUISVILLE, Colo. , March 23, 2017  GlobeImmune, ... purchase agreement for the sale of 12,835,490 shares of ... the  NantWorks  ecosystem of companies. In connection with the sale ... GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 ... common stock. "We are pleased to ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
Breaking Biology News(10 mins):